| Date | Time | Local Time | Room | Session | Role | Topic |
|---|---|---|---|---|---|---|
| 2022-09-16 | 16:06-16:18 | 2022-09-16,16:06-16:18 | Meeting Room 1 |
Oral Presentation 2 |
Speaker | Subcutaneous PD-L1 Antibody ASC22 (Envafolimab) plus Nucleos(t)ide Analogs Achieved Functional Cure of Chronic Hepatitis B in 42.9% of Patients with HBsAg ≤100 IU/mL: Interim Results from a Phase IIb Clinical Trial |